Haldol im in deltoid

In the long-term study in subjects with schizoaffective disorder, the EPS during the 25-week open-label INVEGA SUSTENNA® treatment were hyperkinesia (%), parkinsonism (%), tremor (%), dyskinesia (%), and dystonia (%). During the 15-month double-blind treatment, the incidence of any EPS was similar to that of the placebo group (% and % respectively). The most commonly reported treatment-emergent EPS-related adverse events ( > 2%) in any treatment group in the double-blind phase of the study (INVEGA SUSTENNA® versus placebo) were hyperkinesia (% vs. %), parkinsonism (% vs. %), and tremor (% vs. %).

Haldol im in deltoid

haldol im in deltoid

Media:

haldol im in deltoidhaldol im in deltoidhaldol im in deltoidhaldol im in deltoidhaldol im in deltoid